FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2027-03-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2 study evaluating FOR46 in combination with enzalutamide in patients with
metastatic castration resistant prostate cancer (mCRPC) after prior progression on
abiraterone. FOR46 is designed to target and bind to CD46, a transmembrane cellular protein
expressed at moderate or high levels in numerous cancer types. The investigators hypothesize
that the combination of FOR46 plus enzalutamide will achieve a clinically significant
composite response rate with sufficient durability of response in mCRPC patients.